Back to Search
DONALD N FORTHAL, MD
MD
Infectious Disease Physician
NPI: 1215017363IndividualAccepts Medicare
Specialties, Licenses & Credentials
Infectious Disease PhysicianPrimary
Internal Medicine — Infectious Disease
Code: 207RI0200X
000000G44065(CA)
CMS Specialties
PrimaryINFECTIOUS DISEASE
Education
OTHER
Class of 1979
Research & Publications (20)
Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.
PMID 15681406·J Virol·2005
8-other
Antibody inhibition of cytomegalovirus: the role of natural killer and macrophage effector cells.
PMID 11926747·Transpl Infect Dis·2001
8-other
Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count.
PMID 11350669·AIDS Res Hum Retroviruses·2001
8-other
FcgammaRIIa genotype predicts progression of HIV infection.
PMID 18025239·J Immunol·2007
4-observational
Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate.
PMID 17475891·J Immunol·2007
2-rct
Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.
PMID 16940533·J Virol·2006
7-preclinical
Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells.
PMID 11435575·J Virol·2001
8-other
Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys.
PMID 19553307·J Virol·2009
7-preclinical
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.
PMID 19436712·PLoS Pathog·2009
7-preclinical
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.
PMID 18997770·Nature·2009
7-preclinical
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.
PMID 18842730·J Virol·2008
8-other
Heavily glycosylated, highly fit SIVMne variants continue to diversify and undergo selection after transmission to a new host and they elicit early antibody dependent cellular responses but delayed neutralizing antibody responses.
PMID 18680596·Virol J·2008
4-observational
Fc receptor but not complement binding is important in antibody protection against HIV.
PMID 17805298·Nature·2007
7-preclinical
Antiviral antibodies are necessary for control of simian immunodeficiency virus replication.
PMID 17329327·J Virol·2007
7-preclinical
Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge.
PMID 16951366·J Immunol·2006
7-preclinical
Role of CD8+ cells in controlling replication of nonpathogenic Simian Immunodeficiency Virus SIVmac1A11.
PMID 16584561·Virol J·2006
7-preclinical
A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575.
PMID 15718840·AIDS·2005
3-trial
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.
PMID 15688278·J Infect Dis·2005
3-trial
The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients.
PMID 15535413·Antivir Ther·2004
3-trial
CD8+ T-cell mediated tumor protection by Pseudomonas exotoxin fused to ovalbumin in C57BL/6 mice.
PMID 12717358·Surgery·2003
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- UCI MEDICAL CENTER, 101 THE CITY DRIVE SOUTH
ORANGE, CA 92868 - Phone
- (714) 456-8978
Quick Facts
- NPI
- 1215017363
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 47
- Publications
- 20
Are you this provider?
Claim Your Profile